Yarrow Biosciences
AcquiredFirst-in-class anti-TSHR antibody for autoimmune thyroid diseases
New York, United States · Founded 2021 · $200.0M raised
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- yarrowbioscience.com
- Total Funding
- $200.0M
- Last Round
- $200.0M Series ADec 2025
- Rounds
- 1
About
Yarrow Bioscience is a clinical-stage biotechnology company developing a first-in-class anti-TSHR antibody (YB-101/GS-098) targeting Graves' disease and thyroid eye disease. Signed $1.37B licensing with GenSci; reverse merger with Vyne Dec 2025.
Summary
Yarrow Biosciences is a Biotech company based in New York, United States, founded in 2021. It has raised $200.0M in total across 1 round, most recently a $200.0M Series A round in Dec 2025. Investors include RTW Investments, OrbiMed and Janus Henderson Investors.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2025
Sign up to see all 2 rounds
Series A through Merger — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/yarrow-biosciences"><img src="https://indexed.vc/api/badge/company/yarrow-biosciences" alt="Yarrow Biosciences on Indexed.vc" width="260" height="76" /></a>